Home › Companies › SYNDAX PHARMACEUTICALS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and SYNDAX PHARMACEUTICALS INC.’s Form 8-K, filed May 15, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 15, 2024: 5 items on SYNDAX PHARMACEUTICALS INC.’s Form 8-K, filed May 15, 2024: 5 passed (calculated).
Significant dissent: 1 director (36.9% against).
Notable dissent: 1 director (13.1% against); 1 say-on-pay vote (73.9% support).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore SYNDAX PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are SYNDAX PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 15, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Martin H. Huber, M.D. | 61,876,711 | -- | -- | 736,625 | 3,032,770 | 99% | Passed (calculated) | — |
| Elect Director: Jennifer Jarrett | 39,491,936 | -- | -- | 23,121,400 | 3,032,770 | 63% | Passed (calculated) | — |
| Elect Director: William Meury | 54,416,889 | -- | -- | 8,196,447 | 3,032,770 | 87% | Passed (calculated) | — |
| 2. Advisory vote on executive compensation | 46,228,421 | 16,304,796 | 80,119 | -- | 3,032,770 | 74% | Passed (calculated) | — |
| 3. Ratification of selection of independent registered public accounting firm | 65,371,337 | 253,270 | 21,499 | -- | -- | 99.6% | Passed (calculated) | — |
Source: SYNDAX PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 15, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
218 asset managers disclosed a vote on at least one SYNDAX PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
63% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Jennifer Jarrett
SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jennifer Jarrett”): 39,491,936 for, 23,121,400 withheld, per its Form 8-K filed May 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 63% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 69 asset managers below reported 16,535,343 for, 8,286,958 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,905,246 | 0 | 0 | 0 | For |
| BlackRock | 3,561,811 | 0 | 0 | 0 | For |
| State Street | 3,133 | 0 | 0 | 3,196,274 | Withhold |
| Fidelity | 1,771,614 | 0 | 0 | 0 | For |
| T. Rowe Price | 14,587 | 0 | 0 | 1,353,833 | Withhold |
| FRANKLIN STRATEGIC SERIES | 761,451 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 634,277 | Withhold |
| Columbia Threadneedle | 0 | 0 | 0 | 470,690 | Withhold |
| Hartford | 450,188 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 0 | 0 | 409,750 | Withhold |
| TIAA | 0 | 0 | 0 | 390,922 | Withhold |
| Federated Hermes | 354,664 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 219,075 | Withhold |
| Equitable | 121,199 | 0 | 0 | 76,160 | Mixed |
| John Hancock | 96,114 | 0 | 0 | 93,926 | Mixed |
| Delaware/Macquarie | 0 | 0 | 0 | 180,000 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 138,102 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 0 | 0 | 0 | 137,480 | Withhold |
| Brighthouse | 33,027 | 0 | 0 | 74,650 | Mixed |
| Dimensional | 0 | 0 | 0 | 103,530 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 102,073 | Withhold |
| Prudential/PGIM | 56,452 | 0 | 0 | 39,202 | Mixed |
| Allspring | 0 | 0 | 0 | 94,139 | Withhold |
| Victory Capital | 1,653 | 0 | 0 | 77,970 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 75,145 | Withhold |
Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Martin H. Huber, M.D.
SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Martin H. Huber, M.D.”): 61,876,711 for, 736,625 withheld, per its Form 8-K filed May 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 69 asset managers below reported 24,585,931 for, 236,370 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,905,246 | 0 | 0 | 0 | For |
| BlackRock | 3,561,811 | 0 | 0 | 0 | For |
| State Street | 3,199,027 | 0 | 0 | 380 | For |
| Fidelity | 1,740,912 | 0 | 0 | 30,702 | For |
| T. Rowe Price | 1,368,420 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 761,451 | 0 | 0 | 0 | For |
| Charles Schwab | 634,277 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 470,690 | 0 | 0 | 0 | For |
| Hartford | 450,188 | 0 | 0 | 0 | For |
| JPMorgan | 409,750 | 0 | 0 | 0 | For |
| TIAA | 390,922 | 0 | 0 | 0 | For |
| Federated Hermes | 354,664 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 219,075 | 0 | 0 | 0 | For |
| Equitable | 121,199 | 0 | 0 | 76,160 | Mixed |
| John Hancock | 190,040 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 138,102 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 137,480 | 0 | 0 | 0 | For |
| Brighthouse | 107,677 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 103,530 | Withhold |
| AIG/SunAmerica | 102,073 | 0 | 0 | 0 | For |
| Prudential/PGIM | 95,654 | 0 | 0 | 0 | For |
| Allspring | 94,139 | 0 | 0 | 0 | For |
| Victory Capital | 79,623 | 0 | 0 | 0 | For |
| Lincoln Financial | 75,145 | 0 | 0 | 0 | For |
Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: William Meury
SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: William Meury”): 54,416,889 for, 8,196,447 withheld, per its Form 8-K filed May 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 69 asset managers below reported 20,578,485 for, 4,243,816 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,905,246 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 0 | 3,561,811 | Withhold |
| State Street | 3,199,027 | 0 | 0 | 380 | For |
| Fidelity | 1,691,352 | 0 | 0 | 80,262 | For |
| T. Rowe Price | 1,368,420 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 761,451 | 0 | 0 | 0 | For |
| Charles Schwab | 634,277 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 470,690 | 0 | 0 | 0 | For |
| Hartford | 450,188 | 0 | 0 | 0 | For |
| JPMorgan | 409,750 | 0 | 0 | 0 | For |
| TIAA | 390,922 | 0 | 0 | 0 | For |
| Federated Hermes | 354,664 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 219,075 | 0 | 0 | 0 | For |
| Equitable | 0 | 0 | 0 | 197,359 | Withhold |
| John Hancock | 190,040 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 138,102 | Withhold |
| Exchange Place Advisors Trust | 137,480 | 0 | 0 | 0 | For |
| Brighthouse | 107,677 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 103,530 | Withhold |
| AIG/SunAmerica | 102,073 | 0 | 0 | 0 | For |
| Prudential/PGIM | 95,654 | 0 | 0 | 0 | For |
| Allspring | 94,139 | 0 | 0 | 0 | For |
| Victory Capital | 79,623 | 0 | 0 | 0 | For |
| Lincoln Financial | 75,145 | 0 | 0 | 0 | For |
Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE 2024 PROXY STATEMENT.
SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“2. Advisory vote on executive compensation”): 46,228,421 for, 16,304,796 against, per its Form 8-K filed May 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,655,894 | 4,249,352 | 0 | 0 | Mixed |
| BlackRock | 3,561,811 | 0 | 0 | 0 | For |
| State Street | 3,199,407 | 0 | 0 | 0 | For |
| Fidelity | 1,771,614 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,368,420 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 761,451 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 634,277 | 0 | 0 | Against |
| Columbia Threadneedle | 470,690 | 0 | 0 | 0 | For |
| Hartford | 0 | 450,188 | 0 | 0 | Against |
| JPMorgan | 409,750 | 0 | 0 | 0 | For |
| TIAA | 390,922 | 0 | 0 | 0 | For |
| Federated Hermes | 354,664 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 219,075 | 0 | 0 | 0 | For |
| Equitable | 197,359 | 0 | 0 | 0 | For |
| John Hancock | 93,926 | 96,114 | 0 | 0 | Mixed |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 138,102 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 0 | 137,480 | 0 | 0 | Against |
| Brighthouse | 74,650 | 33,027 | 0 | 0 | Mixed |
| Dimensional | 0 | 103,530 | 0 | 0 | Against |
| AIG/SunAmerica | 102,073 | 0 | 0 | 0 | For |
| Prudential/PGIM | 39,202 | 56,452 | 0 | 0 | Mixed |
| Allspring | 94,139 | 0 | 0 | 0 | For |
| Victory Capital | 77,970 | 1,653 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 25,625 | 0 | 0 | 50,000 | Mixed |
Fund voting reports, all 70 managers: 18,901,000 for, 5,929,186 against, 50,000 withheld, 17,740 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Wellington | 0 | 7,027,115 | 0 | 0 | Against |
| Kynam Capital Management, LP | 0 | 0 | 0 | 5,660,000 | Withhold |
| State Street | 4,702,965 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 3,225,997 | 0 | 0 | 0 | For |
| BlackRock | 3,060,713 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,404,591 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 0 | 2,048,017 | 0 | 0 | Against |
| BVF INC/IL | 1,875,000 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,781,607 | 0 | 0 | 0 | For |
| Avidity Partners Management LP | 0 | 1,752,627 | 0 | 0 | Against |
| ORBIMED ADVISORS LLC | 0 | 1,749,000 | 0 | 0 | Against |
| FRANKLIN ADVISERS INC | 1,394,514 | 0 | 0 | 0 | For |
| Aisling Capital Management LP | 1,025,000 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 999,934 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 930,287 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 900,000 | 0 | 0 | 0 | For |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 0 | 887,094 | 0 | 0 | Against |
| Foresite Capital Management IV, LLC | 875,000 | 0 | 0 | 0 | For |
| JPMorgan | 696,623 | 0 | 0 | 0 | For |
| Northern Trust | 668,691 | 44 | 0 | 0 | For |
| DAFNA Capital Management LLC | 665,574 | 0 | 0 | 0 | For |
| PFM Health Sciences, LP | 658,694 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 634,381 | 0 | 0 | Against |
| Palo Alto Investors LP | 472,600 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 437,716 | 0 | 0 | 0 | For |
Institutional-manager reports, all 168 managers: 32,538,950 for, 15,673,792 against, 5,660,000 withheld, 1,394 abstained, 175 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2024.
SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“3. Ratification of selection of independent registered public accounting firm”): 65,371,337 for, 253,270 against, per its Form 8-K filed May 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the shares present or represented, the standard stated in the company’s proxy statement: votes for exceeded votes against plus abstentions.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 69 asset managers below reported 24,803,846 for, 715 against, 17,740 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,905,246 | 0 | 0 | 0 | For |
| BlackRock | 3,561,811 | 0 | 0 | 0 | For |
| State Street | 3,198,901 | 506 | 0 | 0 | For |
| Fidelity | 1,771,614 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,368,420 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 761,451 | 0 | 0 | 0 | For |
| Charles Schwab | 634,277 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 470,690 | 0 | 0 | 0 | For |
| Hartford | 450,188 | 0 | 0 | 0 | For |
| JPMorgan | 409,750 | 0 | 0 | 0 | For |
| TIAA | 390,922 | 0 | 0 | 0 | For |
| Federated Hermes | 354,664 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 219,075 | 0 | 0 | 0 | For |
| Equitable | 197,359 | 0 | 0 | 0 | For |
| John Hancock | 190,040 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 180,000 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 138,102 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 137,480 | 0 | 0 | 0 | For |
| Brighthouse | 107,677 | 0 | 0 | 0 | For |
| Dimensional | 103,530 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 102,073 | 0 | 0 | 0 | For |
| Prudential/PGIM | 95,654 | 0 | 0 | 0 | For |
| Allspring | 94,139 | 0 | 0 | 0 | For |
| Victory Capital | 79,623 | 0 | 0 | 0 | For |
| Lincoln Financial | 75,145 | 0 | 0 | 0 | For |
Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 84,979,686 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 10.48% |
| 2 | BlackRock | 4.19% |
| 3 | State Street | 3.76% |
| 4 | Fidelity | 2.08% |
| 5 | T. Rowe Price | 1.61% |
| 6 | FRANKLIN STRATEGIC SERIES | 0.90% |
| 7 | Charles Schwab | 0.75% |
| 8 | Columbia Threadneedle | 0.55% |
| 9 | Hartford | 0.53% |
| 10 | JPMorgan | 0.48% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Wellington | 8.27% |
| 2 | Kynam Capital Management, LP | 6.66% |
| 3 | State Street | 5.53% |
| 4 | Eversept Partners, LP | 3.80% |
| 5 | BlackRock | 3.60% |
| 6 | T. Rowe Price | 2.83% |
| 7 | MARSHALL WACE, LLP | 2.41% |
| 8 | BVF INC/IL | 2.21% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2.10% |
| 10 | Avidity Partners Management LP | 2.06% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 8,625,244 | 10.15% | Form 13F, quarter ended March 31, 2024 |
| Entities affiliated with Wellington Group, LLP. | 7,585,221 | 8.93% | Proxy statement (DEF 14A), proxy filed April 2, 2024 |
| Wellington Management | 7,436,616 | 8.75% | Form 13F, quarter ended March 31, 2024 |
| Entities affiliated with BlackRock, Inc. | 7,015,548 | 8.26% | Proxy statement (DEF 14A), proxy filed April 2, 2024 |
| Entities affiliated with Kynam Capital Management, LP | 5,660,000 | 6.66% | Proxy statement (DEF 14A), proxy filed April 2, 2024 |
| Goldman Sachs | 5,486,434 | 6.46% | Form 13F, quarter ended March 31, 2024 |
| Vanguard Group | 5,138,617 | 6.05% | Form 13F, quarter ended March 31, 2024 |
| State Street | 4,819,594 | 5.67% | Form 13F, quarter ended March 31, 2024 |
| S | 3,950,000 | 4.65% | Schedule 13G, filed February 13, 2024 |
| Point72 | 2,066,685 | 2.43% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 84,979,686 shares outstanding, as reported by SYNDAX PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At SYNDAX PHARMACEUTICALS INC.'s shareholder meeting held May 15, 2024, in the 2023-2024 proxy season, 218 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,261 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS… — FOR was 74% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SYNDAX PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 15, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SYNDAX PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
SYNDAX PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “SYNDAX PHARMACEUTICALS (SNDX) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/syndax-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.